The performance of TEPOC and the combination model (TEPOC+CA125) in detecting ovarian cancer in validation cohorts show that the combination model performed significantly better than TEPOC to detect ovarian cancer only in VC2 (P = 0.011, Table S5). The gene discussed is MUC16; the disease is ovarian carcinoma.